Recent News
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).Read Article
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/87FZIogmkW
Dr. John Cush @RheumNow ( View Tweet)
Nordic Registry Study on NSAID use of ~750K, w/ 34-40% under 60 yrs. 48-58% started NSAIDs before Dx of OA. NSAID use incr w/ age from 18 to 55 yrs, then declined. OA pts have a substantial risk of GI complications in all age groups, including those under 60 yrs. Need to consider https://t.co/PLoUVI4Hys
Dr. John Cush @RheumNow ( View Tweet)
CASTLE Phase 1/2a CAR-T cell trial of 24 Tx refractory SLE, SSC, IIM pts w/ MB-CART19.1 (autologous CD19 CAR-T). Good safety (no CRS Gr 2 or higher or ICANS) @wk 24 & 22/24 achieved efficacy (9/10 SLE remission; 9/9 SSc no progression, 4/5 IIM major/mod response). All GC free on https://t.co/1BJidCuCeb
Dr. John Cush @RheumNow ( View Tweet)
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty.
Register: https://t.co/QeIm7OE6yM https://t.co/ToFO4xEFbx
Links:
Dr. John Cush @RheumNow ( View Tweet)
Subcutaneous Anifrolumab Effective in Lupus
ACR
A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients living with moderate-to-severe systemic lupus erythematosus.
Read Article
2025 Rheumatologists, In Memorium
In 2025, Rheumatology lost many of our greatest clinicians, compatriots, and mentors. This is an honor roll for those who cared, taught, advised and supported many patients, and many of us.
Read Article
Data from NHIS surveys show in the USA 24.8 million adults with arthritis reported having an activity limitation AND that the arthritis attributable work limitations in US adults 18-64 yrs affects 38.8%.
https://t.co/Ul2GjrFqfp
https://t.co/Ul2GjrFqfp https://t.co/qzJQwBYDWT
Links:
Dr. John Cush @RheumNow ( View Tweet)
VA registry study; among 2771 RA pts (~65y), 64 (2.3%) had CPPD by ICD9/10 codes. RA+CPPD pts signif older [68 v. 64y], w/ more comorbidity/OA (94 v 80%), spine Dz, DM, but less ACPA (63 v 78%). SNRA+CPPD achieved less LDA, more use of pred & b/tsDMARDs (OR >2), death, TJR. Is https://t.co/hUPJzDseVc
Dr. John Cush @RheumNow ( View Tweet)
AC&R metanalysis of Generalized Joint Hypermobility (GJH) in adults - 46 studies (n=23,000 pts). GJH required 6 or more Beighton criteria, w/ prevalence of 2%, but 5% in young adults (18-25 yrs). Propose Dx thresholds should vary w/ age = ≥6/9 (18-25y), ≥5/9 (26-65y) & ≥4/9 https://t.co/fgDGKwUozh
Dr. John Cush @RheumNow ( View Tweet)
Obesity and Low Back Pain
A large patient population study finds weight gain, increases risk for low back pain - the risk increased 7% for every BMI unit or 10 pounds over ideal weight.
https://t.co/EZQwhLpNjg https://t.co/tIlEQmedp7
Dr. John Cush @RheumNow ( View Tweet)
58 newly Dx #PMR pts (on <8 wks steroids/GC) randomised 1:1 MTX 25 mg/wk or placebo, w/ 24-week GC-tapering protocol. @wk 52 GC-free remission achieved in 80% of MTX vs 46% of placebo pts (risk difference 34%, 1-sided 95% CI: 14%, 1-sided P = .0042) https://t.co/75SLx5LtqZ https://t.co/HtDAJe5VI2
Dr. John Cush @RheumNow ( View Tweet)
Glucocorticoid Injections in Knee Osteoarthritis
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).
Read Article
Adult co-twin study of 1261 pairs, 1/2 Rx w/ metformin. Although metformin Rx Twin had higher BMI, they had significantly less incident peripheral OA (adjusted HR 0.60; 0.44–0.82). @ 10 yrs, 6.7% of treated twins, vs 9.7% of non-treated twins had incident OA, with difference of https://t.co/7KpiGssFSo
Dr. John Cush @RheumNow ( View Tweet)
Systematic review of Difficult-to-treat RA (D2T-RA): 23 articles, 27,987 RA pts from 13 countries - pooled prevalence of D2T-RA was 11.7% (10.9% overall; 13.2% in b/tsDMARDs-treated RA). 47% D2T-RA had persistent inflammatory refractory RA (PIRRA). Prevalence decreased w/ https://t.co/0Gatzbfxid
Dr. John Cush @RheumNow ( View Tweet)
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/WYWeDpiYOh
Dr. John Cush @RheumNow ( View Tweet)
DPC - direct primary care offices run by nurse practitioners - states that allow independent NP practices have NPs opening DPC offices, that operate under a membership model, with pts paying for access to the office services, tests, and imaging. Over 2,300 DPC offices currently
Dr. John Cush @RheumNow ( View Tweet)
APP Pearls “Steroids: Set a stop date upfront, educate on side effects, and teach "every milligram matters." Prevents dependence and eases tapering” - Barbara A. Slusher, MSW, PA-C, DFAAPA, DipACLM
Dr. John Cush @RheumNow ( View Tweet)
Congratulations to Dr. Proton Raman - a world class rheumatologist and research scientist!!! https://t.co/ofzGLsofi0
Dr. John Cush @RheumNow ( View Tweet)
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/fxFcqy13g7
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
DERM on RheumNow Podcast (December 2025)
Comorbidity and Health Management
Telling You Where to Go (12.19.2025)-
APP Controversies and Misconceptions
Therapeutic Updates
IL-23 Inhibition Across Psoriatic Disease* and Inflammatory Bowel Disease†
Sponsored by Johnson & Johnson
Watch Dr. Khattri & Jennifer Labas, MSN, discuss IL-23 inhibition in adults with active PsA, moderate to severe plaque PsO, moderately to severely active UC, & moderately to severely active CD
Read Post
Underserved and Under-treated
RheumNow
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
